Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

Summit Therapeutics plc. have announced a multi-year extension of its exclusive strategic alliance with the research teams of Professor Dame Kay Davies, Professor Steve Davies (Department of Chemistry) and Professor Angela Russell (Departments of Chemistry and Pharmacology) until November 2019, with an option to extend it for a further 12 months, to support and accelerate development of future generation utrophin modulators for the treatment of the progressive muscle wasting disorder, Duchenne muscular dystrophy (DMD).

Summit will continue to sponsor a drug discovery and development programme in the University of Oxford research laboratories to identify and develop oral utrophin modulators for the treatment of DMD. This research programme, originally running to November 2016, will now continue until November 2019 with an option to extend it for a further 12 months. As part of the extension, Summit will increase the funding to £0.83 million a year starting in November 2015.

For further information see: http://hsprod.investis.com/servlet/HsPublic?context=ir.access&ir_option=RNS_NEWS&ir_client_id=4747&item=2261650321178624

Similar stories

REF 2021 results

Nobel Laureate Professor Thomas Südhof ForMemRS delivers 2022 Sherrington Prize Lecture

The annual lecture was given in honour of Sir Charles Sherrington, who was awarded the 1932 Nobel Prize in Physiology or Medicine, by the 2013 Nobel Laureate in Physiology or Medicine.

Professor David Paterson unveils Blue Plaque to honour Sir Charles Sherrington at his long-time Oxford residence

Head of Department Professor David Paterson unveiled an Oxfordshire Blue Plaque commemorating Sir Charles Scott Sherrington (1857 – 1952), OM, Nobel Laureate, founder of neurophysiology, on Thursday 28 April at 9 Chadlington Road, Oxford.

Oxford Parkinson’s Disease Centre awarded £3.8 million to reveal the role of calcium in Parkinson’s

A collaborative research team led by the Oxford Parkinson’s Disease Centre (OPDC) has been awarded a £3.8 million Wellcome Trust Collaborative Award to study the function of calcium in dopamine neurons, and how this is plays a role in Parkinson’s. Their research will help explain how and why dopamine neurons are vulnerable in the disease and look at how they may be preserved.

The effect of nuclear pH on cardiac gene expression

Research led by Dr Alzbeta Hulikova and Professor Pawel Swietach has, for the first time, described the potential regulation of nuclear acid-base chemistry in neonatal and adult cardiomyocytes, and explained its relevance in the context of heart physiology and pathology.